Urine Omics Predicting IO Therapy Responses in mUC Patients

Recruiting now

Conditions studied: Metastatic Urothelial Carcinoma

In brief

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.

Key facts

Study ID
NCT04641936
Run by
National Taiwan University Hospital
People needed
600
Starts
2020-12-17
Expected to finish
2027-10-31
Last updated by the study team
2024-04-17

Who can join

Age: 20 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.